

Topical Collection

OMICs and Complex Diseases

Message from the Collection Editors

Omics, which includes genomes, epigenomics, lipidomics, transcriptomics, proteomics, microbiomics, and metabolomics, is a fast-developing, multi-disciplinary, and growing discipline. In ways that were previously unimaginable, each of these domains provides the opportunity to comprehend and observe science from a global perspective. High-throughput methodologies can rapidly provide a global picture of the processes within cells at multiple levels, allowing for accelerated discoveries in health and disease. Although the results of "omics" are still preliminary and little is known from large epidemiological studies, it is believed that they are inevitably important technologies for future discoveries in health and disease. Recent breakthroughs in "omics" technologies have opened up various new opportunities for novel discoveries in the diagnosis, treatment, and prevention of diseases. These new "omics" technologies have the potential to significantly improve our understanding of the complex relationships that exist between lifestyle (food and nutrients), metabolism, and complex diseases.

Collection Editors

Dr. Mostafa Dianatinasab

Dr. Anke Wesselius

Dr. Amin Salehi-Abargouei



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/161545

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).